PPT-Antiplatelet Therapy for Secondary Prevention in the First Year Following

Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group JeanFrançois Tanguay MD CSPQ FRCPC FACC FAHA FESC Michael P Love MB ChB MD MRCP and Robert C Welsh MD FRCP FACC. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. ASA – NSAID Drug/Drug Interaction. Working Group: . Alan D. Bell, MD, CCFP; Wee . Shian. Chan, MD, FRCP. Objectives. Interpret. . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet therapy in patients . P . Stather. , N . Dattani. , D . Sidloff. On Behalf of VERN. Background. Abdominal Aortic Aneurysm (AAA) increases cardiovascular (CV) risk. NAAASP recommends BP and lipid control. ESVS recommends antiplatelet. GRACE. . 5-Year Mortality . Antiplatelet Therapy. Cornerstone of Medical Therapy Post ACS. TRA 2P-TIMI 50. Efficacy/Safety. ATLAS ACS 2—TIMI 51. Study Design. ATLAS-2. . Baseline Patient Characteristics. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. La gamme de thé MORPHEE vise toute générations recherchant le sommeil paisible tant désiré et non procuré par tout types de médicaments. Essentiellement composé de feuille de morphine, ce thé vous assurera d’un rétablissement digne d’un voyage sur . Presenter: . Meng-Jiun. . Chiou. 5Sep2017. 1. Introduction. Lifelong . antiplatelet. treatment is recommended after . ischaemic. vascular events, on the basis of trials done mainly in patients younger than 75 years. . acute . rheumatic fever . and . rheumatic . heart . disease. Dr Anna Ralph. Clinical Researcher, Menzies School of Health Research. Infectious Diseases Specialist, Royal Darwin Hospital . Learning objectives.